Auris Medical to Redomicile Holding Company from Switzerland to Bermuda
29 janv. 2019 07h30 HE
|
Auris Medical AG
Move to Bermuda will enhance corporate flexibility, reduce costs and provide better alignment with U.S. corporate law Subject to approval by extraordinary general meeting of shareholders ...
Auris Medical Announces Publication of New Data Highlighting the Role of Betahistine in Promoting the Restoration of Forgotten Memories in Mice and Healthy Volunteers
23 janv. 2019 08h30 HE
|
Auris Medical AG
Zug, Switzerland, January 23, 2019 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology...
Auris Medical Provides Update on Intranasal Betahistine Programs
15 janv. 2019 08h30 HE
|
Auris Medical AG
Closes acquisition of Orphan Drug Designation for betahistine for the treatment of obesity associated with Prader-Willi syndrome (PWS) Clinical trial applications for proof-of-concept studies...
Auris Medical Announces Acquisition of Orphan Drug Designation and Secures Rights to In-License Additional Patents Related to Betahistine
06 déc. 2018 07h30 HE
|
Auris Medical AG
Acquires Orphan Drug Designation for betahistine for the treatment of obesity associated with Prader-Willi syndrome (PWS) Signs letter of intent to in-license two US patents covering use of...
Auris Medical Announces Results of Pre-IND Meeting With FDA For AM-201 Program in Olanzapine-Induced Weight Gain
20 nov. 2018 09h20 HE
|
Auris Medical AG
Zug, Switzerland, November 20, 2018 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...
Auris Medical Reports Third Quarter 2018 Financial Results and Provides Business Update
15 nov. 2018 06h45 HE
|
Auris Medical AG
Positive outcomes from second Phase 1 trial with intranasal betahistine Further evidence for betahistine's preventive effects in antipsychotic-induced weight gain Progressing intranasal...
Auris Medical to Report Third Quarter 2018 Financial Results and Provide Business Update on Thursday, November 15, 2018
08 nov. 2018 07h00 HE
|
Auris Medical AG
Zug, Switzerland, November 08, 2018 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...
Auris Medical Announces Positive Results From Second Phase 1 Clinical Trial With Intranasal Betahistine
17 oct. 2018 06h45 HE
|
Auris Medical AG
Bioavailability significantly higher than with oral administration Treatment safe and multiple dosing well tolerated Company to move forward with planned proof-of-concept studies in acute...
Auris Medical to provide update on intranasal betahistine program on Wednesday, October 17, 2018
12 oct. 2018 07h30 HE
|
Auris Medical AG
Zug, Switzerland, October 12, 2018 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology...
Auris Medical Receives FDA Guidance at Type C Meeting for AM-111 in the Treatment of Sudden Sensorineural Hearing Loss
30 août 2018 08h15 HE
|
Auris Medical AG
Zug, Switzerland, August 30, 2018 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology...